NIH Principles of Clinical Pharmacology Syllabus 2023-2024

Module 1: Introduction to Clinical Pharmacology	
Lectures	Post-Lecture Activities
Introduction to Module 1 - Dr. Craig Thomas	
Introduction to Clinical Pharmacology and Therapeutics - Dr. Juan J.L. Lertora	Case Study: Steady-State Calculation
Introduction to Pharmacology, Drug Development and Clinical Pharmacology -	Understanding the Basics of Pharmacology
Dr. William D. Figg	onderstanding the basies of Harmacology
Practical Pharmacology - Dr. Anne Zajicek	Case Study: Practice with Prescriptions
Biochemical Mechanisms for Drug Toxicity - Dr. A. Beasley Green	Case Study: Statins & Hepatotoxicity
Ethics in Pediatric Clinical Pharmacology - Dr. Donna L. Snyder	Case Study: Pediatric Extrapolation
Ethics in Adult Clinical Pharmacology - Dr. Ezekiel J. Emanuel	Principles of Ethics
Module 2: Pharmacokineti	cs
Lectures	Post-Lecture Activities
Introduction to Module 2 - Dr. Anne Zajicek	
Drug Absorption and Bio-availability - Dr. Jan Beumer	Case Study: The Impact of Food on
	Bioavailability
Compartmental Analysis of Drug Distribution - Dr. Arthur Atkinson	Case Study: Effect of Protein Binding on V _d
Noncompartmental vs. Compartmental Approaches to Pharmacokinetic	Case Study: Nonlinear PK Calculation
Analysis - Dr. Paolo Vicini	
Population Pharmacokinetics - Dr. Robert R. Bies	Population Pharmacokinetic Modeling
	Vignette by Dr. Robert R. Bies plus a
	Population Pharmacokinetic Terminology
	Activity
Chemical Analysis of Drugs and Metabolites - Dr. Andrew Goey	Case Study by Dr. Robert Parise: Introduction
	to Mass Spectrometry
Pharmacokinetics & Pharmacodynamics of Therapeutic Proteins – Dr. Bernd	Pharmacologic Characteristics of Therapeutic
Meibohm	Proteins
Module 3: Drug Metabolism and 1	Fransport
Lectures	Post-Lecture Activities
Introduction to Module 3 - Dr. Lisa M. Cordes	
Pathways of Drug Metabolism	Case Study by Dr. Lionel D. Lewis: "Victims &
Part 1: Phase I Drug Metabolism - Dr. Kenneth Thummel	Perpetrators" in Therapeutics
Part 2: Phase II Drug Metabolism - Dr. Deanna Kroetz	
P-Glycoprotein and Drug Transport	Case Study by Dr. Jamy M. Coorge:
	Case Study by Dr. Jomy M. George: Transporter Mediated Drug-Drug Interactions
Part 1: ABC Transporters in Health and Disease - Dr. Michael Gottesman	
Part 2: ABC Transporters in the Blood-Brain Barrier - Dr. Matthew Hall	
Membrane Transport - Dr. Kathy Giacomini	Membrane Transporters in Drug
Dure Transment Assess the Direct Durin Denvice Du California Industry	Development
Drug Transport Across the Blood Brain Barrier - Dr. Sadhana Jackson	Permeability of the Blood Brain Barrier
Module 4: Pharmacokinetics and Drug Therapy	in Special Populations
Lectures	Post-Lecture Activities
Introduction to Module 4 - Dr. Bruce Waldrop	1 <u>-</u>
Pharmacokinetic Considerations in Patients with Renal Impairment - Dr.	Case Study: Drug Dosing in Patients with
Darren Roberts	Chronic Kidney Disease
Pharmacokinetics in Patients Requiring Renal Replacement Therapy	Continuous Renal Replacement Therapy:
Part 1: PK in Patients Requiring Hemodialysis - Dr. Arthur Atkinson	Who, When, Why, How
Part 2: Continuous Renal Replacement Therapy - Dr. Gregory Susla	Case Study Dass Adjustments Dassd -
The Liver and Drugs - Dr. Jürgen Venitz	Case Study: Dose Adjustments Based on

Child-Pugh Score

Dispositionug Therapy in the Geriatric Population - Dr. Darrell R. AbernethyCase Study: DOAarmacokinetics and Obesity - Dr. Manjunath PaiCase Study: DrugModule 5: Assessment of Drug EffectsPost-Lecture Acroduction to Module 5 - Dr. Terry Seatonmarkers of Drug Effects - Dr. Robert SchuckPharmacodynaniarmacodynamic and Pharmacokinetic Modeling of Data - Dr. Joga GobburuPK/PD Modelingease Progression Models - Dr. Diane MouldKey Concepts of Modelingle of Pharmacodynamics in Drug Development - Dr. James DoroshowPharmacodynan BiomarkersModule 6: Drug Discovery and DevelopmenttruresPost-Lecture Ac roduction to Module 6 - Dr. William Zamboni ug Discovery - Dr. Edward Sausvilleuntitative Systems Pharmacology - Dr. D. Lansing TaylorIntegrating Dive Computation M Melanoma tural Products - Dr. Barry O'KeefeDecisions on Scr Biopharmaceuti Biopharmaceuti nsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilars Loga Development in the Pediatric Population - Dr. Anne ZajicekClinical Research	Changes That Influence Drug Cs in the Elderly g Dosing in Obesity	
In the Geriatric Population - Dr. Darrell R. Abernethy Case Study: DOA armacokinetics and Obesity - Dr. Manjunath Pai Case Study: DOA Module 5: Assessment of Drug Effects Post-Lecture Action roduction to Module 5 - Dr. Terry Seaton Pharmacodynamic armacodynamic and Pharmacokinetic Modeling of Data - Dr. Joga Gobburu ease Progression Models - Dr. Diane Mould Key Concepts of Modeling Pharmacodynamics in Drug Development - Dr. James Doroshow Pharmacodynam Biomarkers of Drug Effects - Dr. William Zamboni ug Discovery - Dr. Edward Sausville Drug Discovery and Development goliscovery - Dr. Edward Sausville Drug Discovery Integrating Dive Computation Minimatorial Drug Screening - Dr. Craig Thomas Case Study: BRA Melanoma tural Products - Dr. Barry O'Keefe Decisions on Scr ug Formulation & Delivery - Dr. Robert Ternik Biopharmaceuti Insiderations in the Development of Biologics - Dr. Mansoor Khan Biosimilars ug Development in the Pediatric Population - Dr. Anne Zajicek Clinical Research		
armacokinetics and Obesity - Dr. Manjunath Pai Case Study: Drug Module 5: Assessment of Drug Effects Post-Lecture Ac roduction to Module 5 - Dr. Terry Seaton Pharmacodynamic markers of Drug Effects - Dr. Robert Schuck Pharmacodynamic armacodynamic and Pharmacokinetic Modeling of Data - Dr. Joga Gobburu PK/PD Modeling ease Progression Models - Dr. Diane Mould Key Concepts of Modeling le of Pharmacodynamics in Drug Development - Dr. James Doroshow Pharmacodynam Biomarkers Module 6: Drug Discovery and Development Post-Lecture Ac roduction to Module 6 - Dr. William Zamboni Drug Discovery I antitative Systems Pharmacology - Dr. D. Lansing Taylor Integrating Dive computation M Case Study: BRA melanoma Melanoma tural Products - Dr. Barry O'Keefe Decisions on Scr ug Formulation & Delivery - Dr. Robert Ternik Biopharmaceuti nsiderations in the Development of Biologics - Dr. Mansoor Khan Biosimilars ug Development in the Pediatric Population - Dr. Anne Zajicek Clinical Research		
Module 5: Assessment of Drug EffectsPost-Lecture Acroduction to Module 5 - Dr. Terry Seatonmarkers of Drug Effects - Dr. Robert SchuckPharmacodynamicarmacodynamic and Pharmacokinetic Modeling of Data - Dr. Joga GobburuPK/PD Modelingease Progression Models - Dr. Diane MouldKey Concepts of Modelingle of Pharmacodynamics in Drug Development - Dr. James DoroshowPharmacodynam BiomarkersModule 6: Drug Discovery and DevelopmentDrug Discovery and DevelopmentDrug Discovery and DevelopmentturesPost-Lecture Accomputation to Module 6 - Dr. William Zamboni ug Discovery - Dr. Edward Sausvilleantitative Systems Pharmacology - Dr. D. Lansing TaylorIntegrating Dive Computation Mi Melanomatural Products - Dr. Barry O'KeefeDecisions on Scr Biopharmaceuti nsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilars Biosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research	g Dosing in Obesity	
cturesPost-Lecture Actionroduction to Module 5 - Dr. Terry SeatonPharmacodynamicarmarkers of Drug Effects - Dr. Robert SchuckPharmacodynamicarmacodynamic and Pharmacokinetic Modeling of Data - Dr. Joga GobburuPK/PD Modelingease Progression Models - Dr. Diane MouldKey Concepts of Modelingle of Pharmacodynamics in Drug Development - Dr. James DoroshowPharmacodynam BiomarkersModule 6: Drug Discovery and DevelopmenttturesPost-Lecture Actionroduction to Module 6 - Dr. William ZamboniDrug Discovery I Integrating Dive Computation Modelsantitative Systems Pharmacology - Dr. D. Lansing TaylorIntegrating Dive Computation Melanomatural Products - Dr. Barry O'KeefeDecisions on Scr Biopharmaceutiug Formulation & Delivery - Dr. Robert TernikBiopharmaceutinsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research		
roduction to Module 5 - Dr. Terry Seaton markers of Drug Effects - Dr. Robert Schuck armacodynamic and Pharmacokinetic Modeling of Data - Dr. Joga Gobburu ease Progression Models - Dr. Diane Mould Key Concepts of Modeling le of Pharmacodynamics in Drug Development - Dr. James Doroshow Module 6: Drug Discovery and Development Ctures Module 6 - Dr. William Zamboni Jg Discovery - Dr. Edward Sausville antitative Systems Pharmacology - Dr. D. Lansing Taylor Integrating Dive Computation Melanoma tural Products - Dr. Barry O'Keefe Jg Formulation & Delivery - Dr. Robert Ternik Iside rations in the Development of Biologics - Dr. Mansoor Khan Jg Development in the Pediatric Population - Dr. Anne Zajicek Clinical Research		
markers of Drug Effects - Dr. Robert SchuckPharmacodynamiarmacodynamic and Pharmacokinetic Modeling of Data - Dr. Joga GobburuPK/PD Modelingease Progression Models - Dr. Diane MouldKey Concepts of Modelingle of Pharmacodynamics in Drug Development - Dr. James DoroshowPharmacodynam BiomarkersModule 6: Drug Discovery and DevelopmenttruesPost-Lecture Acroduction to Module 6 - Dr. William Zamboni ug Discovery - Dr. Edward Sausvilleantitative Systems Pharmacology - Dr. D. Lansing TaylorIntegrating Dive Computation M Melanomatural Products - Dr. Barry O'KeefeDecisions on Scr Biopharmaceutiug Formulation & Delivery - Dr. Robert TernikBiosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research	tivities	
armacodynamic and Pharmacokinetic Modeling of Data - Dr. Joga Gobburu PK/PD Modeling ease Progression Models - Dr. Diane Mould Key Concepts of Modeling le of Pharmacodynamics in Drug Development - Dr. James Doroshow Pharmacodynam Biomarkers Module 6: Drug Discovery and Development ctures Post-Lecture Acc roduction to Module 6 - Dr. William Zamboni ug Discovery - Dr. Edward Sausville Drug Discovery I Integrating Dive Computation Melanoma tural Products - Dr. Barry O'Keefe Decisions on Scr ug Formulation & Delivery - Dr. Robert Ternik Biopharmaceuti nsiderations in the Development of Biologics - Dr. Anne Zajicek Clinical Research		
ease Progression Models - Dr. Diane MouldKey Concepts of Modelingle of Pharmacodynamics in Drug Development - Dr. James DoroshowPharmacodynam BiomarkersModule 6: Drug Discovery and DevelopmentDrug Discovery and DevelopmentcturesPost-Lecture Actionroduction to Module 6 - Dr. William Zamboniug Discovery - Dr. Edward SausvilleDrug Discovery Iantitative Systems Pharmacology - Dr. D. Lansing TaylorIntegrating Dive Computation Michanomatural Products - Dr. Barry O'KeefeDecisions on Scr Biopharmaceuti nsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research	nic/Response Biomarkers	
Modelingle of Pharmacodynamics in Drug Development - Dr. James DoroshowPharmacodynam BiomarkersModule 6: Drug Discovery and DevelopmenttruresPost-Lecture Accroduction to Module 6 - Dr. William Zamboniug Discovery - Dr. Edward SausvilleDrug Discovery Iantitative Systems Pharmacology - Dr. D. Lansing TaylorIntegrating Dive Computation Melanomambinatorial Drug Screening - Dr. Craig ThomasCase Study: BRA Melanomatural Products - Dr. Barry O'KeefeDecisions on Scrug Formulation & Delivery - Dr. Robert TernikBiopharmaceutinsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research	Exercise by Dr. Cody J. Peer	
BiomarkersModule 6: Drug Discovery and DevelopmentcturesPost-Lecture Acroduction to Module 6 - Dr. William ZamboniDrug Discovery Iug Discovery - Dr. Edward SausvilleDrug Discovery Iantitative Systems Pharmacology - Dr. D. Lansing TaylorIntegrating Dive Computation Membinatorial Drug Screening - Dr. Craig ThomasCase Study: BRA Melanomatural Products - Dr. Barry O'KeefeDecisions on Scrug Formulation & Delivery - Dr. Robert TernikBiopharmaceutinsiderations in the Development of Biologics - Dr. Anne ZajicekClinical Research	Disease Progression	
Module 6: Drug Discovery and DevelopmentcturesPost-Lecture Acroduction to Module 6 - Dr. William ZamboniDrug Discovery Iug Discovery - Dr. Edward SausvilleDrug Discovery Iantitative Systems Pharmacology - Dr. D. Lansing TaylorIntegrating Dive Computation Membinatorial Drug Screening - Dr. Craig ThomasCase Study: BRA Melanomatural Products - Dr. Barry O'KeefeDecisions on Scr Biopharmaceutiug Formulation & Delivery - Dr. Robert TernikBiopharmaceutinsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research	nic & Proof of Mechanism	
cturesPost-Lecture Actionroduction to Module 6 - Dr. William ZamboniDrug Discovery Iug Discovery - Dr. Edward SausvilleDrug Discovery Iantitative Systems Pharmacology - Dr. D. Lansing TaylorIntegrating Dive Computation Milliammbinatorial Drug Screening - Dr. Craig ThomasCase Study: BRA Melanomatural Products - Dr. Barry O'KeefeDecisions on Scrug Formulation & Delivery - Dr. Robert TernikBiopharmaceuti Biopharmaceutinsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research		
roduction to Module 6 - Dr. William Zamboni ag Discovery - Dr. Edward Sausville Drug Discovery I antitative Systems Pharmacology - Dr. D. Lansing Taylor Integrating Dive Computation Me mbinatorial Drug Screening - Dr. Craig Thomas Case Study: BRA Melanoma tural Products - Dr. Barry O'Keefe Decisions on Scr ag Formulation & Delivery - Dr. Robert Ternik Biopharmaceuti nsiderations in the Development of Biologics - Dr. Mansoor Khan Biosimilars ag Development in the Pediatric Population - Dr. Anne Zajicek Clinical Research		
Lag Discovery - Dr. Edward SausvilleDrug Discovery Iantitative Systems Pharmacology - Dr. D. Lansing TaylorIntegrating Dive Computation Me Computation Me Computation Me Melanomambinatorial Drug Screening - Dr. Craig ThomasCase Study: BRA Melanomatural Products - Dr. Barry O'KeefeDecisions on Scr Biopharmaceuti nsiderations in the Development of Biologics - Dr. Mansoor Khanug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research	tivities	
antitative Systems Pharmacology - Dr. D. Lansing TaylorIntegrating Dive Computation Me Computation Me Case Study: BRA Melanomambinatorial Drug Screening - Dr. Craig ThomasCase Study: BRA Melanomatural Products - Dr. Barry O'KeefeDecisions on Scr Biopharmaceutiug Formulation & Delivery - Dr. Robert TernikBiopharmaceutinsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research		
Computation Membinatorial Drug Screening - Dr. Craig ThomasCase Study: BRA Melanomatural Products - Dr. Barry O'KeefeDecisions on Scr Biopharmaceutiug Formulation & Delivery - Dr. Robert TernikBiopharmaceutinsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research	Basics	
mbinatorial Drug Screening - Dr. Craig ThomasCase Study: BRA Melanomatural Products - Dr. Barry O'KeefeDecisions on Scr Decisions on Scr Biopharmaceutiug Formulation & Delivery - Dr. Robert TernikBiopharmaceutinsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research	rse Data Sources into	
Melanomatural Products - Dr. Barry O'KeefeDecisions on Scrug Formulation & Delivery - Dr. Robert TernikBiopharmaceutinsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research		
tural Products - Dr. Barry O'KeefeDecisions on Scrug Formulation & Delivery - Dr. Robert TernikBiopharmaceutinsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research	F & MEK Inhibitors in	
ug Formulation & Delivery - Dr. Robert TernikBiopharmaceutinsiderations in the Development of Biologics - Dr. Mansoor KhanBiosimilarsug Development in the Pediatric Population - Dr. Anne ZajicekClinical Research		
nsiderations in the Development of Biologics - Dr. Mansoor Khan Biosimilars ag Development in the Pediatric Population - Dr. Anne Zajicek Clinical Research	eening Natural Products	
ag Development in the Pediatric Population - Dr. Anne Zajicek Clinical Research	cs Classification System	
imal Scale Up and First-in-Human Studies - Dr. Jerry Collins Estimating the S		
	n Involving Children	
	n Involving Children tarting Dose in FiH Studies	
Optimization	-	
	tarting Dose in FiH Studies Ikinumab Dosing	
	tarting Dose in FiH Studies Ikinumab Dosing Velopment Path	
Barry Goldspiel	tarting Dose in FiH Studies Ikinumab Dosing	
Module 7: Pharmacogenomics and Pharmacotherapy		

Lectures	Post-Lecture Activities	
Introduction to Module 7 - Dr. Elvin Price		
Pharmacometabolomics: Implications for Clinical Pharmacology - Dr. Richard	Case Study: SSRIs & Pharmacometabolomics	
Weinshilboum		
Overview of Pharmacogenomics - Dr. Howard McLeod	Case Study: Dosing Guidelines for	
	Azathioprine & TPMT	
Implementing Pharmacogenomics into Practice - Dr. Mary Relling	Drugs & Genes	
Pharmacogenomics: FDA Perspective - Dr. Michael Pacanowski	Case Study: Ivacaftor & CFTR	
Clinical Drug Interactions - Dr. Sarah Robertson	Case Study: Clinical Implications of Grapefruit	
	Juice	
Clinical Assessment of Adverse Drug Reactions - Dr. Christopher D. Breder	Case Study: Describing Adverse Events Using	
	CTCAE	
Post-Marketing Drug Safety Surveillance - Dr. Peter Waldron	Case Study: MedWatch Voluntary Reporting	
Quality Assurance for Drug Therapy - Dr. Charles Daniels	Medication Use Evaluation	

Topics of Special Interest (Supplementary Materials)

About This Module:

This Module contains supplementary materials for participants who are interested in learning more. Although these lectures are not classified as core lectures and are not part of the final exam, they will add to the participant's knowledge base on pharmacology.

Supplementary Lectures	Post-Lecture Activities
Use of Positron Emission Tomography (PET) in Pharmacokinetics - Dr. Robert	Basics of PET in PK
Innis	
Drug Transporters in ADME and Drug Action - Dr. Joseph Ware	Case Study: The Mystery of Loperamide
Enabling Technologies in Drug Formulation - Dr. Ping Gao	Understanding Drug Formulations
Computational Methods of Drug Discovery and Design - Dr. Glen Kellogg	Computational Methods Key Definitions
Immunotherapeutics - Dr. James Gulley	Case Study by Dr. Lisa M. Cordes:
	Immunotherapy-Related Adverse Events
T-Cell Therapies: Principles and Practice - Dr. James Yang	Structures of Adoptive Cell Therapies
NCI Drug Development Workshop: How to Advance a Therapeutic Candidate	Case Studies:
from Bench to Bedside	Development of Small Molecule Products
	Development of Biological Products